Nerve Grafts + DBS Surgery for Parkinson's Disease
(CAPNG Trial)

Recruiting in Palo Alto (17 mi)

Overseen byCraig van Horne, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Craig van Horne, MD, PhD

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests the safety of implanting a patient's own nerve tissue into their brain during surgery for Parkinson's disease. The goal is to use natural substances from the nerve tissue to help protect and repair brain cells affected by the disease.

Research Team

Craig van Horne, MD, PhD

Principal Investigator

University of Kentucky

Eligibility Criteria

This trial is for people aged 40-75 with Parkinson's Disease who are already getting deep brain stimulation (DBS) surgery and respond well to Sinemet. They must be able to consent and handle the surgery. It's not for those under 40 or over 75, pregnant or breastfeeding women, or anyone unable to use birth control during the study.

Inclusion Criteria

I respond well to Sinemet medication.

I am medically fit for surgery.

I am receiving deep brain stimulation in specific brain areas.

See 2 more

Exclusion Criteria

I am not pregnant, breastfeeding, and if capable of becoming pregnant, I agree to use birth control during the study.

I am not eligible for deep brain stimulation.

I am unable to understand and agree to the study's details on my own.

See 1 more

Treatment Details

Interventions

Autologous Peripheral Nerve Graft (Other)

Trial OverviewThe study tests implanting nerve grafts from a patient's own body into their brain during DBS surgery. These grafts contain cells that might help neurons survive and function better in Parkinson’s patients.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Peripheral Nerve GraftExperimental Treatment1 Intervention

The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).